Amelioration of experimental autoimmune myasthenia gravis rats by blood purification treatment using 4-mercaptoethylpyridine-based adsorbent

Journal of Biomedical Materials Research - Part A

Volumn 98 A, Issue 4, 2011, Pages 589-595

  Ren, Jun ^a   Bai, Ying ^b   Hao, Lan ^a   Dong, Yan ^c   Pi, Zhiqian ^a   Jia, Lingyun ^a  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^b DALIAN UNIVERSITY   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

4 mercaptoethylpyridine; autoantibody; blood purification; cytokine; myasthenia gravis

Indexed keywords

4-MERCAPTOETHYLPYRIDINE; AUTOANTIBODY; BLOOD PURIFICATION; CYTOKINE; MYASTHENIA GRAVIS;

ADSORBENTS; ADSORPTION; ANTIBODIES; ANTIGENS; GEL PERMEATION CHROMATOGRAPHY; LIGANDS; PURIFICATION; RATS;

BLOOD;

4 MERCAPTOETHYLPYRIDINE; ADSORBENT; CHOLINERGIC RECEPTOR ANTIBODY; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN G; INTERLEUKIN 17; PYRIDINE DERIVATIVE; SEPHAROSE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOSAFETY; BLOOD CELL COUNT; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HEMOPERFUSION; MYASTHENIA GRAVIS; NONHUMAN; RAT; THERAPY EFFECT; TREATMENT OUTCOME;

ADSORPTION; ANIMALS; AUTOANTIBODIES; CYTOKINES; FEMALE; HUMANS; IMMUNOSORBENTS; MATERIALS TESTING; MOLECULAR STRUCTURE; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; PYRIDINES; RANDOM ALLOCATION; RATS; RATS, INBRED LEW; RECEPTORS, CHOLINERGIC;

EID: 80051475228     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.33139     Document Type: Article

References (31)

1. Conti-Fine BM, Milani M, Kaminski HJ,. Myasthenia gravis: Past, present, and future. J Clin Invest 2006; 116: 2843-2854. (Pubitemid 44684466)
2. Vincent A, Palace J, Hilton-Jones D,. Myasthenia gravis. Lancet 2001; 357: 2122-2128. (Pubitemid 32607461)
3. Cornelio F, Antozzi C, Mantegazza R, Confalonieri P, Berta E, Peluchetti D, Sghirlanzoni A, Fiacchino F,. Immunosuppressive treatments, their efficiency on myasthenia gravis patients' outcome and on the natural course of the disease. Ann N Y Acad Sci 1993; 681: 594-602. (Pubitemid 23233888)
4. Beekman R, Kuks JB, Oosterhuis HJ,. Myasthenia gravis: Diagnosis and follow up of 100 consecutive patients. J Neurol 1997; 244: 112-118. (Pubitemid 27057957)
5. Haas M, Mayr N, Zeitlhofer J, Goldammer A, Derfler K,. Long-term treatment of myasthenia gravis with immunoadsorption. J Clin Apher 2002; 17: 84-87. (Pubitemid 34809556)
6. Benny WB, Sutton DMC, Oger J, Bril V, McAteer MJ, Rock G,. Clinical evaluation of a staphylococcal protein A immunoadsorption system in the treatment of myasthenia gravis patients. Transfusion 1999; 39: 682-687. (Pubitemid 29328479)
7. Grob D, Simpson D, Mitsumoto H, Hoch B, Mokhtarian F, Bender A, Greenberg M, Koo A, Nakayama S,. Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology 1995; 45: 338-344.
8. Gjorstrup P, Watt RM,. Therapeutic protein A immunoadsorption. A review. Transfus Sci 1990; 11: 281-302.
9. Ren J, Jia LY, Xu L, Lin X, Pi ZQ, Xie J,. Removal of autoantibodies by 4-mercaptoethylpyridine-based adsorbent. J Chromatogra B 2009; 877: 1200-1204.
10. Guerrier L, Girot P, Schwartz W, Boschetti E,. New method for the selective capture of antibodies under physiological conditions. Bioseparation 2000; 9: 211-221. (Pubitemid 32219010)
11. Roque ACA, Silva CSO, Taipa MA,. Affinity-based methodologies and ligands for antibody purification: Advances and perspectives. J Chromatogra A 2007; 1160: 44-55. (Pubitemid 47078947)
12. Guerrier L, Flayeux I, Boschetti E,. A dual-mode approach to the selective separation of antibodies and their fragments. J Chromatogr B 2001; 755: 37-46. (Pubitemid 32324067)
13. Ghose S, Hubbard B, Cramer SM,. Protein interactions in hydrophobic charge induction chromatography (HCIC). Biotechnol Prog 2005; 21: 498-508. (Pubitemid 40466422)
14. Baggi F, Annoni A, Ubiali F, Milani M, Longhi R, Scaioli W, Cornelio F, Mantegazza R, Antozzi C,. Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats. J Immunol 2004; 172: 2697-2703. (Pubitemid 38182422)
15. Psaridi-Linardaki L, Trakas N, Mamalaki A, Tzartos SJ,. Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor α-subunit. Development of an antigen-specific therapeutic strategy. J Neuroimmunol 2005; 159: 183-191. (Pubitemid 40126191)
16. Takamori M, Maruta T,. Immunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptor. Ther Apher 2001; 5: 340-350. (Pubitemid 34033331)
17. Zhang GX, Navikas V, Link H,. Cytokines and the pathogenesis of myasthenia gravis. Muscle Nerve 1997; 20: 543-551. (Pubitemid 27190745)
18. Christadoss P, Tüzün E, Li J, Saini SS, Yang H,. Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis. Ann N Y Acad Sci 2008; 1132: 210-219. (Pubitemid 351841352)
19. Milani M, Ostlie N, Wang W, Conti-Fine BM,. T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann N Y Acad Sci 2003; 998: 284-307. (Pubitemid 37194171)
20. Tüzün E, Scott BG, Goluszko E, Higgs S, Christadoss P,. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J Immunol 2003; 171: 3847-3854. (Pubitemid 37264927)
21. Christadoss P,. C5 gene influences the development of murine myasthenia gravis. J Immunol 1988; 140: 2589-2592.
22. Zhou YF, Gong BD, Lin F, Rother RP, Medof ME, Kaminski HJ,. Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol 2007; 179: 8562-8567.
23. Soltys J, Kusner LL, Young A, Richmonds C, Hatala D, Gong B, Shanmugavel V, Kaminski HJ,. Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann Neurol 2009; 65: 67-75.
24. Lohr J, Knoechel B, Wang JJ, Villarino AV, Abbas AK,. Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med 2006; 203: 2785-2791. (Pubitemid 46026156)
25. Bai Y, Liu RL, Huang DR, Cava AL, Tang YY, Iwakura Y, Campagnolo DI, Vollmer TL, Ransohoff RM, Shi FD,. Eur J Immunol 2008; 38: 1877-1888.
26. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y,. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006; 177: 566-573. (Pubitemid 43939170)
27. Mu LL, Sun B, Kong QF, Wang JH, Wang GY, Zhang SJ, Wang DD, Liu YM, Liu YX, An HX, Li HL,. Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis. Immunology 2009; 128: 826-836.
28. Wang W, Milani M, Ostlie N, Okita D, Agarwal RK, Caspi RR, Conti-Fine BM,. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells. J Immunol 2007; 178: 7072-7080. (Pubitemid 46847433)
29. Duan RS, Wang HB, Yang JS, Scallon B, Link H, Xiao BG,. Anti-TNF-alpha antibodies suppress the development of experimental autoimmune myasthenia gravis. J Autoimmun 2002; 19: 169-174. (Pubitemid 36262931)
30. Weber V, Linsberger I, Ettenauer M, Loth F, Höyhtyä M, Falkenhagen D,. Development of specific adsorbents for human tumor necrosis factor-alpha: Influence of antibody immobilization on performance and biocompatibility. Biomacromolecules 2005; 6: 1864-1870. (Pubitemid 41052178)
31. Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamura M, Ikeda H, Sakai M,. Cytokine adsorptive property of various adsorbents in immunoadsorption columns and a newly developed adsorbent: An in vitro study. Blood Purif 2004; 22: 530-536. (Pubitemid 40069623)